HK Stock Market Move | MEDBOT-B(02252) rose more than 7% as the unique EDA bronchoscope surgery navigation system received registration approval.

MEDBOT-B (02252) rose by more than 7%, as of the time of publication, it has risen by 7.64%, reaching 22.58 Hong Kong dollars, with a turnover of 2045.01 million Hong Kong dollars. On the news front, on December 24th, MEDBOT-B released an announcement that the bronchoscopy surgery system Siasun Robot & Automation UniPathTM electronic bronchoscopy surgery navigation system (UniPath) independently developed by the Group has officially been approved by the National Medical Products Administration (NMPA). The approval of UniPath by the NMPA this time is a milestone breakthrough in leading the global development of technology and applications in the field of surgical Siasun Robot & Automation, and also signifies that domestic surgical Siasun Robot & Automation has achieved systematic full coverage in key technological paths for minimally invasive diagnosis and treatment. Up to now, the number of products approved for listing in the field of surgical Siasun Robot & Automation by the Group has increased to 7 models, making it the first and currently the only enterprise globally to achieve commercialization of products in all five "golden tracks" of surgical Siasun Robot & Automation. According to reports, the newly approved UniPath is a non-invasive minimally invasive surgical platform through natural cavities, with an ultra-flexible and ultra-thin snake-like Siasun Robot & Automation catheter that can enter narrow lesion spaces that are difficult to reach through the body's natural cavities without surface trauma, playing an important role in the early diagnosis and treatment of early cancer lesions such as small nodules in the lungs.